🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Locally Advanced Esophageal Squamous Cell Carcinoma

Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma NCT06342167Phase 210 sites📍 Beijing📍 Fujian📍 Handan Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Radiotherapy, Programmed Cell Death Protein 1 Inhibitor, Immunonutrition support Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC NCT06510660Phase 21 site📍 Fuzhou Fujian Medical University Union Hospital · Tests: adebrelimab Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study NCT07437898Phase 21 site📍 Putian The Affiliated Hospital of Putian University · Tests: Adebrelimab, chemotherapy Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer NCT06173986Phase 1, Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: PD-1inhibitor, nab-paclitaxel + cisplatin, Radiotherapy A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies NCT05473156Phase 1, Phase 21 site📍 Taipei AP Biosciences Inc. · Tests: AP203, AP203 Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) NCT04807673Phase 31 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Pembrolizumab, Paclitaxel, Cisplatin, neoadjuvant chemoradiotherapy A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma NCT06354530Phase 2, Phase 31 site📍 Chongqing Army Medical Center of PLA · Tests: anlotinib, Thoracic radiotherapy Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma NCT07622797Phase 21 site📍 Luoyang The First Affiliated Hospital of Henan University of Scienc… · Tests: Camrelizumab (anti-PD-1 inhibitor), Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin, Capecitabine, radiotherapy Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC NCT06601309Phase 21 site📍 Fuzhou Fujian Medical University Union Hospital · Tests: Serplulimab, Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy), Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy), Radio… A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC NCT07385001Phase 1, Phase 21 site📍 Xi'an Tang-Du Hospital · Tests: AK112, AK112, AK112 + Neoadjuvant chemotherapy Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer NCT06421376Phase 23 sites📍 Anyang📍 Xinxiang📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) NCT04138212Phase 31 site📍 Zhengzhou Henan Cancer Hospital · Tests: Paclitaxel, Cisplatin, neoadjuvant chemoradiation therapy Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma NCT06056336Phase 21 site📍 Shanghai Guo Xufeng · Tests: Tislelizumab A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma NCT06356688Phase 21 site📍 Nanjing Sun Jing · Tests: Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) NCT06709417Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: Sintilimab, Chemotherapy, radiotherapy A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types NCT07503808Phase 115 sites📍 Denver📍 Sarasota📍 Detroit IDEAYA Biosciences · Tests: IDE034 Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era NCT07858630n/a1 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: GTV-CTV Longitudinal Margin, Regional Lymph Node Irradiation Strategy Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07638436Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Adebrelimab Injection Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma NCT06304350Phase 21 site📍 Shanghai Tongji University · Tests: Combination of pembrolizumab and platinum containing dual drugs A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites📍 Santa Monica📍 New Have📍 Camperdown Kivu Bioscience Inc. · Tests: KIVU-107 Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC NCT07038629Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: S1, Iparomlimab, Radiation A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) NCT07405151Phase 1, Phase 232 sites📍 Pittsburgh📍 Natal📍 Porto Alegre Merck Sharp & Dohme LLC · Tests: I-DXd, Rescue Medication A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy NCT07487896Phase 381 sites📍 Anqing📍 Bengbu📍 Hefei MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL201, Paclitaxel, Docetaxel, Irinotecan Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy NCT06602843NA1 site📍 Hefei Anhui Provincial Hospital · Tests: Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC NCT07733180Phase 24 sites📍 Yokohama📍 Takatsukishi📍 ChuoKu BeOne Medicines · Tests: Tislelizumab, Oxaliplatin, Leucovorin, 5-fluorouracil (5-FU) Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) NCT06187597Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: S-1, Toripalimab, Intensity-modulated radiotherapy Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma NCT05495152Phase 32 sites📍 Zhengzhou📍 Zhengzhou Henan Cancer Hospital · Tests: Sintilimab A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Study of XB010 in Subjects With Solid Tumors NCT06545331Phase 120 sites📍 Irvine📍 Los Angeles📍 Washington D.C. Exelixis · Tests: XB010, Pembrolizumab Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma NCT06675201Phase 21 site📍 Chengdu Sichuan University · Tests: neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy